PURPOSE: To investigate the safety of thrice-daily hyperfractionated radiotherapy (RT) given in conjunction with @entity3600 ( @entity3600 ) in high-grade @entity11 . METHODS AND MATERIALS: @entity1 >18 years old with newly diagnosed high-grade @entity11 were eligible. The dose of radiation was 5040 cGy, with a 1440-cGy boost in 180 cGy fractions delivered thrice daily in two 6-day periods with a 2-week interval. @entity3600 (200 mg/m(2)) was administered on the first day of radiation, then every 7 weeks for 1 year and every 10 weeks for another year. RESULTS: Eighteen @entity1 were enrolled. The mean age was 49.6 years. Sixteen @entity1 had @entity816 (Grade 3 or 4 in 5 and 11 @entity1 , respectively) and 2 had @entity816 (Grade 3 and 4 in 1 @entity1 each). One underwent total resection, 9 subtotal resection, and 8 biopsy only. Thirteen @entity1 had stable disease, 4 regression, and 1 progression. The median time to progression was 37.8 weeks. The median overall survival was 44.4 weeks. Nine @entity1 had @entity137 , including 2 deaths at 69 and 139 weeks. CONCLUSION: This regimen is unacceptably toxic. Factors that could have contributed to the @entity137 may include the total radiation dose, thrice-daily hyperfractionation, and the concurrent use of i.v. @entity3600 .

Safety of thrice-daily hyperfractionated radiation and @entity3600 for high-grade XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'neurologic toxicities'] @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas'] @entity3600 :: ('MESH:D002330', 'Chemical') :: ['BCNU', 'carmustine'] @entity816 :: ('MESH:D001254', 'Disease') :: ['oligoastrocytomas', 'astrocytomas']
@entity11 :: (MESH:D005910,Disease) :: ['gliomas']
